Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Section Content Menu
Skip to Common Links
U.S. Food & Drug Administration
A to Z Index
Follow FDA
FDA Voice Blog
Enter Search terms
Most Popular Searches
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
Drugs
Home
Drugs
Development & Approval Process (Drugs)
Development Resources
Section Contents Menu
Development & Approval Process (Drugs)
Development Resources
Drug Interactions & Labeling
Drug Development and Drug Interactions
Drug Development and Drug Interactions: Possible Models for Decision-Making
Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers
Drug Development and Drug Interactions: Advisory Committee Meetings
Drug Development and Drug Interactions: Meetings
Drug Development and Drug Interactions: Publications
Drug Development and Drug Interactions: Regulatory Guidance and Manual for Policies and Procedures
Drug Development and Drug Interactions: Related Links
Drug Development and Drug Interactions: Working Group Members
Drug Interaction Presentations
Preventable Adverse Drug Reactions: A Focus on Drug Interactions
-
Cytochrome P450 2C19
Absent in 20–30% of Asians, 3–5% Caucasians
Primary metabolism of:
Diazepam
Phenytoin
Omeprazole
Inhibited by:
Omeprazole
Isoniazid
Ketoconazole
Back to Learning Module
-
-